Hikma Pharmaceuticals (HIK) Stock Rating Reaffirmed by Morgan Stanley

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “equal weight” rating reiterated by investment analysts at Morgan Stanley in a research note issued on Friday. They presently have a GBX 1,100 ($14.73) target price on the stock. Morgan Stanley’s price target suggests a potential upside of 6.69% from the company’s current price.

Other analysts have also issued research reports about the company. Numis Securities restated an “add” rating and issued a GBX 1,560 ($20.89) target price on shares of Hikma Pharmaceuticals in a report on Friday, August 11th. Peel Hunt reaffirmed a “hold” rating and issued a GBX 2,150 ($28.79) price target on shares of Hikma Pharmaceuticals in a research report on Thursday, August 17th. Jefferies Group lowered their price target on Hikma Pharmaceuticals from GBX 1,390 ($18.62) to GBX 1,045 ($13.99) and set a “hold” rating on the stock in a research report on Monday, August 21st. Goldman Sachs Group downgraded Hikma Pharmaceuticals to a “neutral” rating and lowered their price target for the company from GBX 2,600 ($34.82) to GBX 1,310 ($17.54) in a research report on Tuesday, August 22nd. Finally, Citigroup reaffirmed a “neutral” rating and issued a GBX 1,350 ($18.08) price target on shares of Hikma Pharmaceuticals in a research report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. Hikma Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of GBX 1,186 ($15.88).

Hikma Pharmaceuticals (LON:HIK) opened at GBX 1,031 ($13.81) on Friday. Hikma Pharmaceuticals has a one year low of GBX 906.50 ($12.14) and a one year high of GBX 2,346 ($31.42).

TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/01/hikma-pharmaceuticals-hik-stock-rating-reaffirmed-by-morgan-stanley.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply